Keywords: crucell, revenues, up, three-fold, dutch, biotechnology, firm
Crucell's revenues up three-fold in 2004
Article | 14 February 2005
Dutch biotechnology firm Crucell has reported a significant three-fold increase in 2004 revenues, which reached 22.6 million euros ($30.9 million). Cash burn was 10.5 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
